Session: 273. Transplant ID: Bacterial Infections Saturday, October 5, 2019: 12:15 PM

Background: Patients colonized by multidrug-resistant bacteria (MDR) have high risk for infection after hematopoietic stem cell transplantation (HSCT). Probiotic is a strategy that can be used to decolonize patients. Our aim was to describe the impact of use of *Lactobacillus plantarum* (LP) on decolonization, MDR infections and intestinal microbiome (IM) of autologous HSCT patients colonized by vancomycin-resistant *Enterococcus* (VRE) and carbapenem-resistant Gram-negative (CRGN).

Methods: A prospective study was conducted at Hospital das Clinicas of University of Sao Paulo Brazil from 2017 to 2018. Candidates for auto-HSCT colonized by MDR received LP in capsules, 5×10^9 CFU twice daily until neutropenia (NP). Rectal swabs were performed and cultured using selective media as well as PCR for carbapenemases, *vanA* and *vanB*. Stool samples for IIM analysis were collected weekly as baseline (before LB use) until the NP. The V4 region of 165 rDNA gene were sequenced by Ion Torrent PGM and analyzed using alpha and β diversities by Qiime. Demographic and clinical data including previous antibiotics use were evaluated; CDC criteria was applied for colonization and infection.

Results: All of seven patients were colonized by VRE and CRGN (Table 1). Only one patient remained colonized by CRGN after 61 days of LP. Four patients developed seven bloodstream infections (BSI) during the NP, two of them by CRGN. There was no infection caused by VRE neither by LP. One patient, with low adherence to LP use (66%), died due to MDR *K. pneumoniae* BSI. We observed a decrease of Clostridia, Verrucomicrobiae, *Blautia* and an increase of Enterobacteriaceae. Baseline samples from patients who used TMP/SMX had higher concentrations of Bacteroidetes when compared with those who had not use it. The Shannon index in controls ranged 1.98–5.55 and during NP 1.15–5.99. The β diversity analysis showed no clear patterns between patients.

Conclusion: We observed a heterogeneity among IM of auto-HSCT patients prior and after LP. It was not possible to establish an IM pattern, probably, because of small number of patients. Although, clinical infections by CRGN occurred despite of LP use, no cases of colonization and infection by VRE were identified. Thus, it seems that LP is a good and safe strategy to decolonized HSCT.




Table1. Demographic, clinical characteristics and IM of seven auto-HSCT.

Disgressis n % Multiple Mychona 2 29% Modgkin's /mphoma 4 57% Modgkin's /mphoma 1 14% Acte Mychold Leukemia 1 14% Acte Mychold Leukemia 3 43% 18 - 59 years 3 43% Resolvers 4 57% MOR Colonization 7 100% Kenumonine 4 57% A. Bourmanini 3 43% BE/M (carmustine, etoposide, aracytin and melphalan) 1 14% Bu V(busulian and melphalan) 1 14% Buseline 5 71% Att is actam · inhibitor 1 14% Fuorequinotion 2 29% Antitingal 0 0% Antitingal 1 14% Fuorequinotione 1 14% Fuorequinotione 1 14% Stationamide 4 57% Aratisuagal 0 0%	Characteristics		
Multiple Mysiona229%Multiple Mysiona237%Acute Mysiola Caskemia114%Modein Mysiona343%Solar Same Markami57%36%Same Markami57%36%More Casca57%36%MOR Casca67%36%MOR Casca67%36%MOR Casca67%36%MOR Casca67%36%MOR Casca67%36%MOR Casca67%36%MOR Casca67%36%More Casca67%36%More Casca67%36%Marka67%36%Marka67%36%Marka67%36%Marka67%36%Marka7%36%Marka67%36%Marka67%36%Marka7%36%Marka7%36%Marka7%36%Marka67%36%Marka7%36%Marka7%36%Marka7%36%Marka7%36%Marka7%36%Marka7%36%Marka7%36%Marka7%36%Marka7%36%Marka7%36%Marka7%36%Marka7%36%Marka7%36%Marka7%36%Marka7% </td <td></td> <td>n</td> <td>*</td>		n	*
Hodgkink symphoma457%Acter Mycloid Leukemia114%Acter Mycloid Leukemia114%Acter Mycloid Leukemia343%18 - 59 years343%18 - 59 years40More Conduction457%Koncolation343%UK Colonation343%UK Colonation343%UK Colonation343%UK Colonation343%UK Colonation343%UK Colonation343%UK Colonation343%UK Colonation343%UK Colonation571%UK Colonation343%UK Colonation343%UK Colonation443%UK Colonation343%UK Colonation343%UK Colonation443%UK Colonation443%UK Colonation343%Sutorention443%Jactar Inhibitor114%Theoreation343%Antilongai229%Antilongai343%Colonation444%Colonation444%Colonation444%Colonation444%Colonation444%Colonation444%Colonation444%Colonation444%Colonation <td< td=""><td></td><td></td><td></td></td<>			
Acit environment11AgeSequer343%Sequer457%Gender57%57%Gender57%57%MDR Constation343%Contiguing Therapy343%EdM (arrowing the clopoids, aracylin and melphalan)114%BedM (arrowing the clopoids, aracylin and melphalan)114%EdM (arrowing the clopoids, aracylin and melphalan)114%BedM (arrowing the clopoids, aracylin and melphalan)114%BedM (arrowing the clopoids, aracylin and melphalan)114%De de lactant e inhibation114%Edm (arrowing the clopoids, aracylin and melphalan)114%De de lactant e inhibation114%Telescale143%Sufforandide33Sufforandide33Sufforandide34Constation14Telescale14Sufforandide34Sufforandide34Constation14Polymyin14Constation24Sufforandide34Sufforandide34Sufforandide34Sufforandide44Sufforandide34Sufforandide34Sufforandide44Sufforandide34Sufforandide44<			
Age Series Selp vars 3 43% 18 - 59 yars 3 43% 18 - 59 yars 3 45% Konder Wars 7 Wors 4 50% MOR Colonization 8 45% Kondinoing 4 60% Conditioning Theray 1 45% EEMA (comustine, etoposide, arscylin and melphalan) 1 45% Bu Vel (busulin and melphalan) 1 45% Du do f Nation Collection of samples 1 45% Du do f Lange (collection of samples) 1 45% Du do f Lange (collection of samples) 1 45% Du do f Lange (collection of samples) 1 45% Du do f Lange (collection of samples) 1 45% Du do f Lange (collection of samples) 1 45% Du do f Lange (collection of samples) 1 45% Du do f Lange (collection of samples) 1 45% Du do f Lange (collection of samples) 1 45%			
sãosãosão15-30 years36.37%15-30 years5.37%5.37%Condor85.37%MDR Colonation36.37%MDR Colonation36.37%K pneumonie36.37%Abumonie36.37%EMA (strauting texpoide, arscyln and melphalan)11.48%BLA (strauting texpoide, arscyln and melphalan)11.48%BLA (strauting texpoide, arscyln and melphalan)11.48%Bu (strauting texpoide, arscyln and argent arge			1400
13 - 59 years 6 57% Gender Wennen 6 57% MDR Colonisation 8 57% MDR Colonisation 3 43% KP Colonisation 8 45% A bournonni 3 43% KP Colonisation 8 45% A bournonni 3 43% BU MG (southan and melphalan) 1 43% Bu MG (southan and melphalan) 1 45% Att and melphalan) 1 45% Att as used by number of patients 1 45% Bustafie and melphalan) 1 46% Flacas used by number of patients 1 16%		3	43%
Gender Jump Women 4 57% MDR Colonation 9 40% MDR Colonation 4 43% Aburnancine 4 43% Conditioning Therapy 9 43% EdM (carrowing tecpopidie, racytin and melphalan) 1 44% Bu/ Qi (buutin and nelphalan) 1 44% Bu/ All (buutin and nelphalan) 1 44% Sufforandié 1 44% Colonation 1 44% Sufforandié		-	
Yournen 4 57% MDR Colonisation 7 100% Visit 6 57% A bournenini 3 43% Conditioning Therapy 8 43% Bit of constraints in etophalan) 3 43% Bit of constraints in etophalan) 3 43% Bit of constraints in etophalan) 1 14% Bit of constraints in etophalan) 1 14% Bit of constraints in etophalan) 1 14% Bit of social soc			
	Women	4	57%
Vief 9 00% Kpermannia 4 80% A. bourmanni 3 43% Conditioning Therapy 1 14% BEAM (consultine, etopoxilia, marcytin and melphalan) 1 14% Bu Mol (sourtham etopoxilian) 1 14% Bu Mol (sourtham etopoxilian) 1 14% Bu Mol (sourtham etopoxilian) 1 14% Bu Mol (sourtham eto dysalian) 5 71% ATB class used by number of patients 1 14% Ruorequino long 2 43% Safformation 1 14% Phoroquino long 3 43% Safformation 2 43% Safformatio 3 43% Safformatio 3 43% Safformatio 2 43% Safformatio 3 43% Safformatio 1 44% Phoroquino long 2 43% Safformatio 1 44% Phoroquino long <td></td> <td></td> <td></td>			
※のののの前で 3 4 57% Abourdonnin 3 43% Conditioning Therapy 8 43% EXAL (carrows (inc. etpopide, sracytin and melphalan) 1 1 14% BAC (structures (etpopide, sracytin and melphalan) 1 1 14% BAC (structures (etpopide, sracytin and melphalan) 1 1 14% Bac (Structures (etpopide, sracytin and melphalan) 1 1 14% Use of AB in collection of samples 5 7.5% Neutropania 5 7.5% Relaxes with holitor 1 1.4% Tubercures (etcoles attic att		7	100%
Å. barmonili 3 43% Å. barmonili 3 43% BEAM (carmustine, etoporida, max (th and melphalan) 1 14% BU M (tosulfan and melphalan) 1 14% Bu M (tosulfan and melphalan) 5 71% Busdine 5 71% Nutropenia 5 71% ATB calection of samples 2 14% Busdine 5 71% ATB cales used by number of patients 2 14% Burdine and melphalan) 1 14% Burdine and melphalan 2 45% AtB cales used by number of patients 2 45% AtB cales used by number of patients 3 45% Burdine and melphalan 2 45% Stafformalide 3 45% Antifungal 2 45% Antifungal 1 14% Paroquinolon 1 14% Cabapaenen 1 14% Cabapaenen 1 14% <tr< td=""><td></td><td></td><td></td></tr<>			
Conditioning Therapy V EAM (carrowing recipotide, aracytin and melphalan) 1 45% Bu Q (Jusuifa and cyclophosphamide) 1 16% Bu Q (Laurifa and melphalan) 1 16% Ure of ATB in Collection of samples 7% Busching 5 7% Neutroppnil 5 7% Statistica Mathematica Mathmatica Mathmatica Mathematica Mathematica Mathmatica Mathematica		3	
BEAM (crumulatine, etdopoidly, analytin, and melphalam) 3 43% BEAM (crumulatine, etdopoidly, analytin, and melphalam) 1 14% Bix of (bix usifin and melphalam) 5 71% Attop (consulting and melphalam) 5 71% Atto and melphalam) 5 71% Atto and melphalam) 1 14% Nutropenia 2 71% Atto and melphalam) 1 14% Nutropenia 1 14% Flactorestation 1 14% Taberculsation 3 43% Safformande 2 0% Antifungat 0 0% Antifungat 1 14% Floorequinolone 1 14% Floorequinolone 1 14% Antifungat 2 2% Antifungat 2 2% Antifungat 1 14% Cobapenem 1 14% Antifungat 2 2% Antifungat			
Bu ζ γ (koustranti and γ ockonstranti metholi and meth		3	43%
10 Mod (ossufan and melpha)n) 1 (14%) Der of AT 16 nolection of samples Taseline 5 73% ATB class used by number of patients baseline 5 (14%) Det aller in 16%) Bet al lactan + inhibitor 1 (14%) Fluoraguinolane 3 (14%) Fluoraguinolane 3 (14%) Antifungal 0 (0%) Antifungal 0 (15%) Antifungal 1 (14%) Suforamide 1 (14%) Cabagenem 1 (14%) Cabag			
Use of Rin Incluction of samples 7% Beakine 7% Neutropenia 7% Neutropenia 7% Steas and submeber of patients 1 Steas and submeber of patients 1 Beakine 1 Beakine 1 Beakine 3 Beakine 3 Beakine 4 Floorequinologica 3 Stafforandie 0 Antifungal 0 Antifungal 1 Polymynin 1 Catapaeren 1 Stafforandie 2 Antifungal 2 Stafforandie 1 Antifungal 2 Stafforandie 2 Stafforandie 2 Stafforandie 3 Stafforandie 3 Stafforandie 3 Stafforandie 3 Stafforandie 3 Stafforandie 3 Stafforandie 4			
Baseline 5 71% Naturdpenia 5 71% ATB class used by number of patients 5 71% ATB class used by number of patients 1 14% baseline 1 14% Fluorequisation 1 14% Fluorequisation 3 43% Sufforande 6 57% Antifungal 0 0% Antifungal 1 14% Fluorequisation 1 14% Fluorequisation 1 14% Fortympin 1 14% Chapapenen 1 14% Sufforande 2 29% Antitungal 1 14% <trtr> Sufforande 2</trtr>			
Neutropenia 5 7,8 ATB class und ynother of pallen 1 Betalenar inhibiton 1 4,8% Toberculotatik 3 4,3% Sulforamide 3 4,3% Sulforamide 3 4,3% Antifungal 0 0,5% Polerculotatik 1 4,4% Antifungal 0 0,6% Antifungal 1 1,4% Polymynin 1 1,4% Chabpanema 1 1,4% Oxacolifonne 1 1,4% Oxacolifonne 1 1,4% Antinogal 2 2,9% Antifungal 1 1,4% Antifungal 1 1,4% Antifungal 2 9,2% Shoff Social 1 1,4% Antifungal 2 9,2% Antifungal 2 9,2% Antifungal 3 2,3% Antifungal 3 2,3% <td></td> <td>5</td> <td>71%</td>		5	71%
ATB class used by number of patients baseline baseline 1 14% Beta lactan+ inhibitor 1 14% Fluoraquinolane 3 43% Sufforande 6 57% Antifungal 0 0% Antifungal 2 29% Proorequinolane 1 14% Fluoraquinolane 2 29% Antifungal 0 0% Antifungal 1 14% Conspanema 1 14% Conspanema 1 14% Sufforanide 2 29% Antifungal 1 14% Conspanema 1 14% Sufforanide 2 29% Antifungal 1 14% Sufforanide 2 29% Antifungal 3 29% Antifungal 2 29% Antifungal 2 29% Sufforanide 3 29%			
baseline baseline 1 4% Tuberculostic 1 4% 14% Tuberculostic 3 43% 43% Sulforantide 3 43% 43% Sulforantide 4 57% 57% Antifungal 0 0% 67% Antifungal 1 4% 78% Polymytin 1 44% 14% Cabapenem 1 44% 14% Otazotilonne 1 44% 14% Antifungal 2 02% 47% Antifungal 1 44% 14% Otazotilonne 1 4% 14% Antifungal 2 02% 47% Antifungal 2 02% 47% Sulforantide 3 02% 25% Sulforantide 3 02% 25% Sulforantide 2 02% 47% Antifungal 2 02% 47% Sulforantide 3 02% 25% Sulforantide 4 04% 25% Sulforantide 1 04% 3 04% <		5	1110
Beta lactana 14% Beta lactana 14% Fluoroquinchone 3 43% Sufonamide 6 57% Antitivagi 0 0% Antitivagi 2 29% Beta lactana inhibitor 1 14% Fluoroquinchone 1 14% 1 Fluoroquinchone 1 14% 1 Chapapemen 1 14% 1 14% Sufformatide 2 29% 1 14% Antivingi 3 29% 29% 1 14% Sufformatide 3 29% 29% 1 14% Sufformatide 3 29% 29% 1 14%			
Tuber:colatilic 1 44% Funcorquinolone 3 43% Suffonandie 6 9% Antifungal 0 0% Antifungal 0 0% Antifungal 1 44% Polymotin 1 14% Polymotin 1 14% Cabapenem 1 14% Otacolifione 1 14% Antinogi 1 14% Antifungal 2 9% Antifungal 1 14% Antifungal 1 14% Antifungal 2 9% Antifungal 1 14% Antifungal 2 9% Shi hSCT 1 4% Shi NSCT 2 9% Shi SSCN 1 14% Shi SSCN 1 14% Shi SSCN 1 14% Shi SSCN 1 14% Shi SSCN 1		1	14%
Fluoroquincione 3 43% Antifungal 6 57% Antifungal 0 0% Antifungal 2 29% Beta lactam - linbilitor 1 14% Ciabapanem 1 14% Antifungal 1 14% Antifungal 1 14% Stim HSCT T 1 Stim HSCT T 1 Stim SON 3 29% Adherence to If (mean 84%) 1 14% Stim SON 1 14% Stim S	Tuberculostatic		14%
Sufforande 4 57% Sufforande 2 28% Antifungal 0 0% Antifungal 1 14% Polymophin 1 14% Polymophin 1 14% Cabapanem 1 14% Oxacolifonne 1 14% Antinogi (schapanem 2 92% Antifungal 1 14% Antifungal 2 92% Shi hSCT 1 4% Shi soft 3 2 Soft Soft 1 14% Soft Soft 1 1 Soft Soft 1 1 Soft Soft 1 1 Soft Soft 1 1 <td< td=""><td>Fluoroquinolone</td><td>3</td><td></td></td<>	Fluoroquinolone	3	
Antihungal 0 0% Antihural 2 29% Antihural 1 14% Fucorogonino 1 14% Polymynin 1 14% Catabahem 14% 14% Sufformanide 2 24% Antinungkycoside 1 14% Antihungkycoside 2 14% Antihungkycoside 1 14% Antihungkycoside 2 25% Shi IntSCT T 14% Shi IntSCT T 14% Shi Ni SCT T 14% Shi Ni SCT T 14% Shi Ni SCT T 15% Shi SCH		4	
Antivinal 2 28,28 Intercorpencia 1 14,64 Heroraquinolora 1 14,64 Polymyrin 1 14,64 Carbapener 1 14,64 Oxazolifonneria 1 14,64 Oxazolifonneria 1 14,64 Antinoglycoside 1 14,64 Antifungal 1 14,64 Antifungal 1 14,64 Antifungal 2 9,29 Antifungal 3 2,39 Antifungal 3 2,39 Antifungal 3 2,39 Antifungal 3 2,39 Antifungal 4 1,49 Syst S70% 1 4,39 Syst S70% 1 4,34 Syst S90% 2 9,39		0	
neutropenia 1 Piarotaguinolone 1 14% Piarotaguinolone 1 14% Onazoldinore 1 14% Chapemen 1 14% Onazoldinore 1 14% Antinorgi/scolide 2 29% Antinorgi/scolide 1 14% Antinorgi/scolide 2 29% Antinorgi/scolide 1 14% Antinorgi/scolide 2 29% Antinorgi/scolide 3 29% Antinorgi/scolide 3 29% Adherence to If (mean 84%) 1 14% Stix / S70% 1 14% Stix / S90% 3 43% Stix / S90% 2 29%		2	29%
Beta lactars - inhibitor 1 14% Polymytin 1 14% Polymytin 1 14% Cabapane 1 14% Otazo filomania 1 14% Otazo filomania 2 26% Antinogi positionania 1 14% Antinogi positionania 2 26% Antinogi positionania 1 14% Antinogi positionania 1 14% Antinogi positionania 2 26% Antinogi positionania 2 25% Sin MSCT 1 4% Sin	neutropenia	_	
Polymynin 1 14% Carbapener 1 14% Orazolikone 2 26% Aminoglycoside 2 29% Aminoglycoside 1 14% Antifungal 2 29% Antifungal 1 14% Antifungal 3 20% Skin MSCT 3 25% Soft 50% 570% 1 14% St% 590% 3 45% St% 590% 2 9%		1	14%
Polymynin 1 14% Carbapener 1 14% Orazolikone 2 26% Aminoglycoside 2 29% Aminoglycoside 1 14% Antifungal 2 29% Antifungal 1 14% Antifungal 3 20% Skin MSCT 3 25% Soft 50% 570% 1 14% St% 590% 3 45% St% 590% 2 9%	Fluoroquinolone	1	14%
Carbapenem 1 14% Obazolikinove 1 14% Sulforandet 2 28% Antidragi 1 14% Antidragi 1 14% Antidragi 1 14% Antidragi 1 14% Shin MSCT 7 7 Yet 3 29% Adherence to If (mean 84%) 7 1 S0% 570% 1 14% S1% 450% 3 43% S1% 50% 3 43% S1% 50% 2 29%		1	14%
54/foramide 2 29% Anthong/xoofde 1 14% Anthong/xoofde 1 14% Anthong 2 10% BSI In HSCT 7 1% Test 0 1% Adverse to IP (mean 84%) 50% 570% 1 1 14% 550% 570% 1 14% 81% 590% 2 29%		1	14%
54/foramide 2 29% Anthong/xoofde 1 14% Anthong/xoofde 1 14% Anthong 2 10% BSI In HSCT 7 1% Test 0 1% Adverse to IP (mean 84%) 50% 570% 1 1 14% 550% 570% 1 14% 81% 590% 2 29%	Oxazolidinone	1	14%
Antifugal 1 14% Antifugal 7 100% BSin HSC 71% 3 25% Adherence to LP (mean 84%) 8 25% 3 25% S0% < 70%	Sulfonamide	2	29%
Antifugal 1 14% Antifugal 7 100% BSin HSC 71% 3 25% Adherence to LP (mean 84%) 8 25% 3 25% S0% < 70%	Aminoglycoside	1	14%
BS in ISCT 71% Vet 4 71% No 3 29% Adherence to LP (mean 84%) 0 0% S5% 0 1% 71% 1 14% 71% 1 14% 71% 3% 3 43% 51% 5/0% 2 29% 29%	Antifungal		14%
BS in ISCT 71% Vet 4 71% No 3 29% Adherence to LP (mean 84%) 0 0% S5% 0 1% 71% 1 14% 71% 1 14% 71% 3% 3 43% 51% 5/0% 2 29% 29%	Antiviral	7	100%
No. 3 29% Adherence to LP (mean 84%) SSが、プログロングの1 1 14% 70% 50% 70% 1 14% 81% 590% 3 43%			
Adherence to LP (mean 84%) 0 0% S50% 0 1 14% DS % 70% 1 14% 1 14% 71% s00% 1 14% 1 43% 91% s100% 3 43% 3 43%	Yes	4	71%
\$50% 0 0% \$50% 10% 14% \$18,850% 1 14% \$18,850% 3 43% \$15,60% 2 29%	No	3	29%
\$50% 0 0% \$50% 10% 14% \$18,850% 1 14% \$18,850% 3 43% \$15,60% 2 29%	Adherence to LP (mean 84%)		
71%≤80% 1 14% 81% ≤90% 3 43% 91% ≤100% 2 29%	≤50%	0	0%
81% ≤ 90% 3 43% 91% ≤ 100% 2 29%	50% ≤ 70%	1	14%
91% ≤ 100% 2 29%	71%≤ 80%	1	14%
	81% ≤ 90%	3	43%
	91% ≤ 100%	2	29%
LP consumption (Median 29; SD ±23)	LP consumption (Median 29; SD ±23)		
≤10 days 0 0%	≤10 days	0	0%
11≤30 days 4 57%	11≤30 days	4	57%
31≤50 days 1 14%	31≤50 days	1	14%
51≤80 days 1 14%		1	14%
81≤90 days 1 14%	81≤90 days	1	14%

Disclosures. All authors: No reported disclosures.

2666. De-escalation of Broad-Spectrum Antibiotics in Hematopoietic Stem Cell Transplant Patients During Initial Episode of Febrile Neutropenia Lindsev Rearigh, DO¹; Erica J, Stohs, MD, MPH¹; Alison Freifeld, MD¹;

Lindsey Rearigh, DO¹; Erica J. Stohs, MD, MPH¹; Alison Freifeld, MD¹; Andrea Zimmer, MD¹; ¹University of Nebraska Medical Center, Omaha, Nebraska

Session: 273. Transplant ID: Bacterial Infections Saturday. October 5, 2019: 12:15 PM

Background: Febrile neutropenia (FN) is a common and serious complication in patients undergoing hematopoietic stem cell transplant (HSCT). Typically, broad-spectrum antibiotics (BSA) are promptly initiated with controversy on timing of de-escalation. ECIL 2013 guidelines suggest de-escalation after 72 hours if the patient is infection free and afebrile for at least 48 hours. Conversely, the 2011 IDSA recommends continuing BSA in patients who defervesce until absolute neutrophil count (ANC) recovery. In 2014, our center's practice changed to early de-escalation and we sought to compare outcomes between the two practices.

Methods: We retrospectively analyzed patients who underwent a HSCT in 2013 and 2017 with an episode of FN and negative infectious work up. The standard care group (SCG) were continued on BSA until ANC recovery. The early de-escalation group (EDG) de-escalated to fluoroquinolone prophylaxis at least 24 hours prior to ANC recovery after the patient was fever free for 48 hours. The primary end-point was duration of BSA. Secondary endpoints included 30-day mortality, re-hospitalization and length of stay (LOS) from FN. Median values were compared with the Mann–Whitney test.

Results: Among 229 HSCT patients, 155 (68%) developed FN post-transplant and of those 97 (63%) were without infection (13 EDG and 84 SCG). Initial FN duration of BSA was less in the EDG (3.09 days vs. 4.69 days, P = 0.069). Total antibiotic free days to 30 day follow-up were similar (EDG 24.08 vs SCG 25.19, P = 0.81). Duration of neutropenia was less in the SCG with 7.99 days compared with 1.69 days in the EDG (P = 0.007), but duration of initial fever was less in the EDG (2.55 days vs. 3.33 days, P = 0.023). 30 day mortality was 0% in both groups. Rates of re-hospitalization within 30 days were approximately the same (7.1% vs. 7.6%). LOS from FN was not significantly different with 6.68 days in SCG and 7.75 days in EDG (P = 0.140). More new bacterial infections were identified within 30 days of FN in the SCG than the EDG (10.7% vs. 7.6%).

Conclusion: Early BSA de-escalation resulted in no significant difference in LOS from FN and fewer days of BSA with 30-day mortality and re-hospitalization rates similar. This data suggest de-escalating BSA prior to ANC recovery is likely safe and leads to less BSA exposure, but more multi-center data are needed.

Disclosures. All authors: No reported disclosures.

2667. Does Ceftazidime-Avibactam (CAZ-AVI) Improve Short- and Long-Term Outcomes Among Solid-Organ Transplant (SOT) Recipients with Carbapenem-Resistant Enterobacteriaceae (CRE) Infections?

Jonathan Sun, DO; Cornelius J. Clancy, MD; Ryan K. Shields, PharmD, MS; Minh-Hong Nguyen, MD; University of Pittsburgh, Pittsburgh, Pennsylvania

Session: 273. Transplant ID: Bacterial Infections

Saturday, October 5, 2019: 12:15 PM

Background: SOT recipients are an ideal population in which to study the impact of new antibiotics, since they are particularly dependent upon drug activity to clear infections. In 3/15, FDA approved CAZ-AVI, the first new anti-CRE agent to arrive in the clinic. Our objective was to determine whether CAZ-AVI improves short- and long-term outcomes of CRE-infected SOT recipients.

Methods: We performed a retrospective study of SOT recipients infected with CRE since 2012, who were treated with CAZ-AVI or salvage agents for \geq 3 days.

Results: 35 CRE-infected SOT recipients (14 liver, 11 lung, 6 kidney, 3 intestine, 1 heart) with bacteremia (20), pneumonia (11), intra-abdominal abscess (3) and soft-tissue infection/osteomyelitis (1) were enrolled. 16 and 19 patients (pts) were treated with CAZ-AVI and salvage agents, respectively. Types of infection or SOT, APACHE II and McCabe scores did not differ significantly between patients treated with CAZ-AVI or salvage agents. 30- and 90-d mortality rates were significantly lower among SOT recipients treated with CAZ-AVI (0% and 6%, respectively) compared with salvage agents (26% and 37%; P = 0.049 and 0.047). Among patients who survived 90 days, recurrent CRE infections were diagnosed in 53% and 17% of those treated with CAZ-AVI and a salvage regimen, respectively (P = 0.10). Median time from end of therapy for the 1st CRE infection to recurrent infection was 116 days (max 1,242) and 361 days (max 799) for CAZ-AVI and salvage regimens, respectively. Survival and recurrence-free survival were greater for treatment with CAZ-AVI and salvage agents, respectively, as measured by Kaplan-Meier (Figures). CAZ-AVI resistance developed in 37% (n = 3) of patients with recurrent infections. Recurrent isolates were genetically indistinguishable from parent isolates by core genome SNP phylogeny (< 15 SNP).

Conclusion: CAZ-AVI significantly reduced short-term mortality among SOT recipients with CRE infections compared with salvage regimens, but was limited by recurrent infections and emergence of resistance. The same strains caused recurrent and initial infections, suggesting that CAZ-AVI did not eliminate CRE from GI sites that serve as sources of recurrence. Optimizing outcomes in SOT recipients with CRE infections will require new agents like CAZ-AVI, and strategies to eliminate long-term colonization.